Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois 60616


The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.


Inclusion Criteria: - lifestyle limiting claudication, rest pain or minor tissue loss - ABI < 0.9 or TBI < 0.5 if ABI is >0.9 - Stenosis (>50%) or occlusion of native SFA >5cm - Orifice and 1 cm of SFA are patent - Popliteal artery is patent at the intercondylar fossa of the femur to the trifurcation - At least 1 patent run off vessel - Guidewire and deliver system successfully traversed the lesion Exclusion Criteria: - Untreated flow-limiting aortoiliac occlusive disease - Any previous stenting or surgery in the target vessel - Femoral or popliteal aneurysm of target vessel - No patent tibial arteries - Prior ipsilateral femoral artery bypass - Major distal amputation (above the transmetatarsal) in either limb - Patients with known sensitivity to Heparin



Primary Contact:

Principal Investigator
Richard Saxon, MD
North County Radiology Medial Group Inc.

Backup Contact:


Location Contact:

Chicago, Illinois 60616
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.